Version history

{
  "session_id": "sess_SDA-2026-04-15-gap-debate-20260410-112441-f2afffb3_20260416-035307",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: SST/PV Interneuron Dysfunction in Alzheimer's Disease\n\n## Question 1: Highest Translational Potential Hypotheses\n\nBased on the current Alzheimer's therapeutic landscape—dominated by amyloid-targeting agents with modest efficacy and significant side effects—I identify three hypotheses with the strongest translational potential:\n\n### Hypothesis A: Interneuron Dysfunction as Primary Pathology (Model B)\n**Rationale**: This model opens a therapeutic avenue orthogonal to amyloid, addressing a mechanism that persists even after amyloid removal. Given the ceiling effects observed with anti-amyloid antibodies (27-35% slowing of progression in pivotal trials), identifying downstream drivers is critical. If interneuron loss is primary, preservation strategies could extend clinical benefit beyond amyloid clearance.\n\n### Hypothesis B: Amyloid–Interneuron Interaction as Stratification Biomarker\n**Rationale**: Not all amyloid-positive individuals progress similarly. Interneuron vulnerability may explain the \"amyloid non-responder\" phenotype—patients who clear amyloid but continue to decline. Testing interneuron biomarkers in ongoing lecanemab/donanemab extension studies could identify subpopulations needing add-on therapy. This is immediately feasible given the active trial infrastructure.\n\n### Hypothesis C: SST/PV-Selective Vulnerability as Mechanistic Target\n**Rationale**: If specific molecular features (e.g., parvalbumin calcium buffering, metabolic demands) explain selective interneuron vulnerability, this creates a precision therapeutic target. This has the highest risk but also the highest reward if validated.\n\n---\n\n## Question 2: Evidence, Safety, and Patient Population Fit\n\n### Hypothesis A: SST/PV Function Preservation\n\n**Current Clinical Evidence**\n\n| Source | Finding | Stage |\n|--------|---------|-------|\n| Verret et al., 2012 | PV+ basket cell loss precedes plaque formation in APP/PS1 mice | Preclinical |\n| two | CSF somatostatin declines in MCI/AD, correlates with cognitive decline | Clinical (exploratory) |\n| Campdelacreu et al. | Lower cortical SST in AD postmortem | Postmortem |\n\nThe clinical evidence is largely correlative",
  "tokens_used": "548"
}